

Janssen Research & Development *

Clinical Protocol

Protocol Title

A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2, + Best Supportive Care Versus Best Supportive Care for Metastatic Castration-resistant Prostate Cancer

KLK2-compPAS

Short Title

Pasritamig vs Placebo in late line Metastatic Castration-resistant Prostate Cancer (mCRPC)

Protocol 78278343PCR3001; Phase 3

Version: Original

JNJ-78278343 (pasritamig)

*Janssen Research & Development is a global organization that operates through different legal entities in various countries/territories. Therefore, the legal entity acting as the sponsor for Janssen Research & Development studies may vary, such as, but not limited to Janssen Biotech, Inc.; Janssen Products, LP; Janssen Biologics, BV; Janssen-Cilag International NV; Janssen, Inc; Janssen Pharmaceutica NV; Janssen Sciences Ireland UC; Janssen Biopharma Inc.; or Janssen Research & Development, LLC. The term “sponsor” is used throughout the protocol to represent these various legal entities; the sponsor is identified on the Contact Information page that accompanies the protocol.

Studies conducted at sites in the United States (US) will be conducted under US Food & Drug Administration Investigational New Drug (IND) regulations (21 CFR Part 312).

Studies conducted at sites in the European Economic Area (EEA) will be conducted under Regulation [EU] No 536/2014.

IND: 157066

EU TRIAL NUMBER: 2025-520927-26

Status: Approved

Date: 22 April 2025

Prepared by: Janssen Research & Development, LLC

EDMS number: EDMS-RIM-1382868, 2.0

GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, and applicable regulatory requirements.

Confidentiality Statement

The information provided herein is considered trade secrets, commercial or financial, or privileged or confidential information that we customarily hold close and treat as confidential. The information is being provided under the assurance that the recipient will maintain the confidentiality of the information under the applicable statutes, regulations, rules, case law, contractual provisions, protective orders, or as otherwise necessary to protect the information from disclosure. The recipient agrees and acknowledges that release of information considered trade secrets, commercial or financial, or privileged or confidential will result in competitive harm and, as such, the information provided herein is exempt from disclosure under the Freedom of Information Act (“FOIA”), or other similar law or regulation. Particularly, the information shall not be utilized in any AI solutions, including GenAI, without Company's prior written approval.

CONFIDENTIAL – FOIA or other similar exemptions apply

1

Status: Approved, Date: 22 April 2025

1. PROTOCOL SUMMARY

1.1. Synopsis

A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2, + Best Supportive Care Versus Best Supportive Care for Metastatic Castration-resistant Prostate Cancer

IND: 157066

EU TRIAL NUMBER: 2025-520927-26

Pasritamig vs Placebo in late line Metastatic Castration-resistant Prostate Cancer (mCRPC)

Pasritamig (JNJ-78278343) is a humanized, IgG1-based, bispecific antibody designed to direct T cells (through binding to CD3 receptor complex) to hK2 (encoded by *KLK2* gene and hereafter referred to as KLK2) on target cells, leading to the activation of the T cells and T-cell-mediated lysis of KLK2-bearing cells.

OBJECTIVES AND ENDPOINTS

Primary objective: To determine if pasritamig + BSC compared to placebo + BSC is superior in OS.

Hypothesis

The hypothesis is that pasritamig + BSC will demonstrate improved OS, compared to placebo + BSC in participants with mCRPC.

OVERALL DESIGN

Key aspects of the trial design are summarised in this table.

Study Model:	Parallel group, 2 treatment groups	Population Type:	Adult patients
Control:	Placebo + BSC	Population Diagnosis or Condition:	mCRPC in the late-line setting
Study Treatment Assignment Method:	2:1 randomization, stratified by prior PSMA-targeted radioligand therapy, prior taxane, and ECOG performance status	Population Age:	≥18 years of age
Blinding	Double-blind	Site Distribution:	Multinational
Sub-studies	No		

Approximately 663 participants with mCRPC will be randomly assigned in this study in a 2:1 ratio to receive pasritamig IV + BSC or placebo IV + BSC. All participants must be receiving background ADT or had prior orchiectomy. All participants may receive BSC (defined as palliative external beam radiation, low dose steroids, pain medication, bone sparing agents, and needed palliative procedures) at the discretion of the physician.

The end of study/study completion is considered as the last scheduled study assessment for the last participant in the study.

